NCT02193828 2017-10-05Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease NodulesEndo PharmaceuticalsPhase 2 Completed76 enrolled 17 charts